A Study of Disease Progression and Anti-HIV Treatments - Full Text View

Purpose

To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.

Condition	Intervention	Phase
HIV Infections	Drug: Lamivudine	Phase II

MedlinePlus related topics:

AIDS

Drug Information available for:

Zidovudine Lamivudine Didanosine Zalcitabine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Placebo Control, Parallel Assignment, Efficacy Study

Official Title:	Influence of Risk Status for Disease Progression on the Response to Antiretroviral Interventions: A Follow-Up Study to ACTG 175

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment:

210

Eligibility

Ages Eligible for Study:	12 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Patients must have:

Prior participation on protocol ACTG 175.

PER AMENDMENT 8/27/96:

Patients must be on study/on treatment at the time the protocol study treatment is extended.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001068

Show 59 Study Locations

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

More Information

Publications:

Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1337-44.

Study ID Numbers:	ACTG 303
First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00001068
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Zalcitabine

Didanosine

Drug Therapy, Combination

AIDS-Related Complex

Antiviral Agents

Zidovudine

Lamivudine

Study placed in the following topic categories:

Sexually Transmitted Diseases, Viral

Acquired Immunodeficiency Syndrome

Zalcitabine

Disease Progression

Zidovudine

Lamivudine

AIDS-Related Complex

Immunologic Deficiency Syndromes

Virus Diseases

Didanosine

HIV Infections

Sexually Transmitted Diseases

Retroviridae Infections

Additional relevant MeSH terms:

Anti-Infective Agents

RNA Virus Infections

Disease Attributes

Anti-HIV Agents

Slow Virus Diseases

Immune System Diseases

Molecular Mechanisms of Pharmacological Action

Enzyme Inhibitors

Infection

Antiviral Agents

Pharmacologic Actions

Reverse Transcriptase Inhibitors

Pathologic Processes

Anti-Retroviral Agents

Therapeutic Uses

Lentivirus Infections

Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on December 03, 2008

Sponsored by:	National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00001068